|
|
|
| home > white papers > Clinical Trials in Russia Orange Paper: 1st Quarter 2014 - Synergy Research Group |
|
|
 WHITE PAPERS |
|
Synergy Research Group
|
|
Clinical Trials in Russia Orange Paper: 1st Quarter 2014
|
|
In summary, Russia remains a very popular geography for local, regional,
and global pharmaceutical companies to conduct clinical trials.
Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4.
Low cost: Average per patient cost is 60% to 70% below US and European
prices due to the low cost of Investigators and the high concentration
of patients in therapeutically aligned medical centers
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research
Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018
merger of CRF Health and Bracket, today launched as Signant Health
(signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT,
Clinical Supplies and Endpoint Quality into the industry’s most
comprehensive patient-centric suite, Signant makes it easier to
participate in – and sites and study teams to run – clinical trials.
This intense focus on the patient experience, deep therapeutic area
expertise and global operational scale enable sponsors and CROs to
extend the reach of drug development, expand patient opportunities and
improve data quality.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
ELRIG Drug Discovery 2019 – Looking Back to the Future
5-6 November 2019, ACC, Liverpool
Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at
ACC in Liverpool.
This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions
assessing how we got to where we are now and setting the challenges for discovering the
drugs of the future. These will be followed by cutting edge talks and examples of new
directions in drug discovery.
Our scientific programme will feature over 40 world-class speakers with 6 main session
tracks. In partnership with key academic and charitable groups, we will also run joint
disease and biology-oriented tracks focusing on the basic sciences that underpin
successful drug discovery.
More info >> |
|
|
|
